Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SID1903 (Dapagliflozin/Sitagliptin) FDC vs Loose Combination in Healthy Volunteers
NCT05453786Phase 1Completed
- Sponsor
- SK Chemicals
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin and sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by SK Chemicals. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Time t up to 72 hours and Maximum Plasma Concentration up to 72 hours. Started Jun 2022; status: completed.
02
Drugs
dapagliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05453786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453786.